Xella Health Launches as Female-Specific Diagnostics Platform

As preventive health platforms like Function take off, Xella uses bloodwork and AI-powered biomarker sequencing to help women detect over 130 female-specific conditions

Xella Health, a new digital health platform made explicitly for women, has launched to address the historical gaps in diagnostic precision, clinical research and healthcare dedicated to female biology, already with a 15,000-woman waitlist.

Powered by AI, Xella pairs advanced testing with longitudinal care to understand root causes of underlying conditions and health concerns.

Operating under the tagline, “Your Health Decoded,” platform sequences billions of data points across clinical and biomarker information to detect over 130 female-specific conditions across various life stages, such as polyendocrine metabolic ovarian syndrome (PMOS, formerly known as PCOS), perimenopause and endometriosis.

Its founders, Kelly Lacob, Adriana Dantas and Jesus Ching, developed the concept while collaborating on molecular diagnostics.

“Women have been trapped in a diagnostic dark age experiencing debilitating symptoms like severe period pain, bloating and GI issues, exhaustion, and brain fog, routinely dismissed by the healthcare system,” said Lacob, who serves as Xella’s CEO.

“This dismissal results in women being diagnosed 4 years later than men, on average, for the same conditions, and a 7-to-10-year delay for women to receive an accurate diagnosis for conditions like endometriosis,” Lacob added. “Stalling necessary care and treatment results in prolonged suffering with chronic pain, heightened infertility risks and declining mental health.”

How It Works

The process begins with an onboarding questionnaire and a blood draw at local partner labs like Quest or Labcorp, or for an additional cost, phlebotomists are available to come to a member’s home.

The proprietary AI software then sequences biomarker data from genomics, proteins, hormones and clinical inputs like symptoms, lifestyle risks and medical history to screen for any conditions specific to female biology.

The data is then processed through Xella’s own CLIA-certified and CAP-accredited dry lab to produce results that can be translated into a personalized healthcare roadmap. From there, members are paired with a certified telehealth physician to go over findings and build an immediate clinical action plan — that could include personalized hormone therapy or referrals to specialists such as genetic counselors, pelvic floor physical therapists and reproductive endocrinologists.

“Women’s health data has historically been treated in isolated silos — a hormone test here, an ultrasound there — but no one was connecting the dots across the entire biology,” said co-founder and chief operating officer Dantas “By tracking unique biological patterns longitudinally across cycles and life stages, we aren’t just providing data, but a clear path forward.”

The science-backed company includes clinical advisors Dr. Allison Kurian, director of Stanford Women’s Clinical Cancer Genetics Program and Professor of Medicine, Epidemiology and Population Health at Stanford, and Dr. Lynn Westphal, reproductive endocrinology and infertility specialist and chief medical officer of Kindbody, along with others at Mammoth Biosciences, Roche, Becton Dickinson, and GRAIL.

Xella also received $4.7 million in angel and pre-seed funding from Precursor Ventures, Capital F, Ulu Ventures, Swizzle Ventures and other funds, as well as strategic angel investors across healthcare, diagnostics and consumer technology.

The new platform emerges as biomarker and blood testing companies like Function Health continue taking off, with personalized healthcare becoming the industry norm. Other wellness brands are following suit, as biohacker and longevity pioneer Bryan Johnson recently launched his own testing platform as part of his company Blueprint, while wearables like Whoop are beginning to offer blood testing and lab panels to create a wider, more holistic picture of health.